US Lawmakers Want Answers From FDA On Infant Formula Shortage Following Abbott Recall
Executive Summary
House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.
You may also be interested in...
US FDA Turns To Temporary Enforcement Discretion For Boosting Infant Formula Supply
FDA launches temporary enforcement discretion on infant formula product to help increase supply in US on same day consent decree announced to allow Abbott to restart production at facility closed since February, prompting ongoing formula shortage.
Weighing Shortage Risk, FDA Clears Releasing Metabolic Formulas Made At Abbott’s Closed Plant
With Michigan facility closed as cause of bacterial contamination is investigated, FDA announces “has no objection” to Abbott releasing specialty and metabolic formulas “to individuals needing urgent, life-sustaining supplies” on a case-by-case basis.
Recall Sours Abbott’s Infant Formula Results; COVID-19 Test Sales Expected To Cool
Worldwide nutrition sales, adult as well as infant products, during Q1 dropped reported 7% to $1.89bn. US sales were $59m, well below $288m in prior-year period.